Rchr
J-GLOBAL ID:200901001582655175   Update date: Jan. 17, 2024

Shimozuma Kojiro

シモヅマ コウジロウ | Shimozuma Kojiro
Affiliation and department:
Job title: Professor
Other affiliations (2):
Research field  (6): Digestive surgery ,  General surgery, pediatric surgery ,  Hygiene and public health (non-laboratory) ,  Hygiene and public health (laboratory) ,  Healthcare management, medical sociology ,  Clinical pharmacy
Research keywords  (1): health services research, health outcomes research, pharmacoeconomics, clinical oncology, palliative medicine
Research theme for competitive and other funds  (26):
  • 2019 - 2020 医薬品・医療機器等の費用対効果評価における公的分析と公的意思決定方法に関する研究
  • 2018 - 2019 医療経済評価の政策応用に向けた評価手法およびデータの確立と評価体制の整備に関する研究
  • 2017 - 2018 医療経済評価を用いた意思決定のための標準的な分析手法および総合的評価の在り方に関する研究
  • 2016 - 2017 医療経済評価の政策応用に向けて標準的手法およびデータの確立と評価体制の整備に関する研究
  • 2015 - 2016 医療経済評価の政策応用に向けた評価手法およびデータの標準化と評価のしくみの構築に関する研究
Show all
Papers (269):
MISC (1):
Books (60):
  • The Ethics of health care rationing - An introduction
    岩波書店 2017 ISBN:9784000612203
  • Methods for the Economic Evaluation of Health Care Programmes (Fourth Edition)
    篠原出版社 2017 ISBN:9784884123956
  • これからの乳癌診療2017-2018 第6章 トピックス 2.高額薬剤と乳がん診療-医療経済の立場から
    金原出版株式会社 2017 ISBN:9784307203685
  • CANCER BOARD OF THE BREAST・patient-reported outcome measures (PROMs)
    メディカルレビュー社 2017 ISBN:9784779218361
  • 基礎から学ぶ医療経済評価
    じほう 2015
more...
Lectures and oral presentations  (48):
  • Subjective and objective assessment of efficacy of frozen gloves and socks to prevent nab-paclitaxel-induced peripheral neuropathy in patients with breast cancer
    (2018 San Antonio Breast Cancer Symposium 2018)
  • Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial
    (2018 San Antonio Breast Cancer Symposium 2018)
  • Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, pha
    (2018 San Antonio Breast Cancer Symposium 2018)
  • Importance of Criteria for Drug Reimbursement Decision- Making for Non-Life-Threatening Diseases
    (International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Europe 2018 2018)
  • Health-Related Quality of Life in Japanese Patients with Prostate Cancer Using EQ-5D-5L and FACT-P: Comparisons According to Treatment Type
    (International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Asia Pacific 2018 2018)
more...
Education (2):
  • - 1985 Osaka University Graduate School of Medicine Graduate School of Medicine
  • - 1981 Yamaguchi University Faculty of Medicine Department of Medicine
Professional career (1):
  • Ph.D. in Medical Science (Osaka University)
Work history (10):
  • 2008/04/01 - Ritsumeikan University Department of Biomedical Sciences, College of Llife Science
  • 2007/04 - 2008/03 Ritsumeikan University Department of Bioscience and Biotechnology, College of Science and Engineering
  • 2002/04 - 2007/03 University of Marketing and Distribution Sciences Faculty of Service Industries, Department of Hospital and Welfare Service
  • 2001/04 - 2002/03 日本医師会総合政策研究機構 主任研究員
  • 1992/04 - 2001/03 Kawasaki Medical School
Show all
Awards (4):
  • 2015/05 - 関西医科大学同窓会 関西医科大学 丹家雛子賞
  • 2005 - 流通科学大学 研究奨励賞
  • 2004 - 流通科学大学 研究奨励賞
  • 1987 - 山口大学医学会 山口大学医学会 小西賞
Association Membership(s) (17):
The Association for Palliative Medicine ,  Japan Association for Bioethics ,  Japan Health Economics Association ,  Japan Psycho-Oncology Society. ,  JAPANESE SOCIETY OF PUBLIC HEALTH ,  Japan Society for Healthcare Administration ,  Japan Association of Breast Cancer Screening ,  JAPAN SURGICAL ASSOCIATION ,  Japan Association of Endocrine Surgeons ,  Japanese Society for Palliative Medicine (JSPM) ,  Japanese Breast Cancer Society (JBCS) ,  Japanese Society of Medical Oncology ,  Japan Society of Clinical Oncology (JSCO) ,  Japan Surgical Society ,  International Society for Quality of Life Research (ISOQOL) ,  International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ,  American Society of Clinical Oncology (ASCO)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page